HRP20020934B1 - 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis - Google Patents
5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesisInfo
- Publication number
- HRP20020934B1 HRP20020934B1 HR20020934A HRP20020934A HRP20020934B1 HR P20020934 B1 HRP20020934 B1 HR P20020934B1 HR 20020934 A HR20020934 A HR 20020934A HR P20020934 A HRP20020934 A HR P20020934A HR P20020934 B1 HRP20020934 B1 HR P20020934B1
- Authority
- HR
- Croatia
- Prior art keywords
- methanesulfonylphenyl
- bipyridinyl
- chloro
- synthesis
- methyl
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical group C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20801700P | 2000-05-26 | 2000-05-26 | |
PCT/US2001/016566 WO2001092230A1 (en) | 2000-05-26 | 2001-05-22 | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis |
Publications (2)
Publication Number | Publication Date |
---|---|
HRP20020934A2 HRP20020934A2 (en) | 2005-02-28 |
HRP20020934B1 true HRP20020934B1 (en) | 2012-01-31 |
Family
ID=22772880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20020934A HRP20020934B1 (en) | 2000-05-26 | 2002-11-25 | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis |
Country Status (49)
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6858631B1 (en) | 1999-11-29 | 2005-02-22 | Merck & Co., Inc. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl |
DK1248618T3 (da) | 1999-11-29 | 2006-07-10 | Merck Frosst Canada Inc | Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
US6521642B2 (en) * | 2000-05-26 | 2003-02-18 | Merck & Co., Inc. | 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis |
ES2562981T3 (es) | 2009-02-27 | 2016-03-09 | Cadila Healthcare Limited | Un procedimiento para la preparación de Etoricoxib |
WO2012004677A1 (en) | 2010-07-05 | 2012-01-12 | Actavis Group Ptc Ehf | Solid state forms of etoricoxib salts |
EP2714676B1 (en) | 2011-05-27 | 2019-04-24 | Farma GRS, d.o.o. | A process for the preparation of polymorphic form i of etoricoxib |
EP2773618A1 (en) | 2011-11-03 | 2014-09-10 | Cadila Healthcare Limited | An improved process for the preparation of etoricoxib and polymorphs thereof |
WO2013075732A1 (en) | 2011-11-21 | 2013-05-30 | Synthon Bv | Process for making crystalline form i of etoricoxib |
EP2601952A1 (en) | 2011-12-07 | 2013-06-12 | Zentiva, k.s. | Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses |
WO2014041558A2 (en) | 2012-08-27 | 2014-03-20 | Glenmark Pharmaceuticals Limited; Glenmark Generics Limited | Process for preparation of crystalline etoricoxib |
EP2887924B1 (en) | 2012-08-27 | 2017-03-29 | Cadila Healthcare Limited | Pharmaceutical compositions of etoricoxib |
CN104418799A (zh) * | 2013-09-03 | 2015-03-18 | 天津药物研究院 | 一种依托考昔的晶型及其制备方法和应用 |
WO2015036550A1 (en) | 2013-09-13 | 2015-03-19 | Synthon B.V. | Process for making etoricoxib |
CN106632003B (zh) * | 2015-12-31 | 2019-02-12 | 上海博志研新药物技术有限公司 | 一种依托考昔的制备方法 |
CN108069896B (zh) * | 2016-11-11 | 2022-08-12 | 昆明积大制药股份有限公司 | 一种依托考昔晶型的制备方法 |
CN107417599B (zh) * | 2017-06-21 | 2020-06-09 | 四川尚锐生物医药有限公司 | 一种依托考昔晶型的制备方法 |
CN107056691B (zh) * | 2017-06-21 | 2020-03-10 | 四川尚锐生物医药有限公司 | 一种制备依托考昔晶型v的方法 |
MX2017009660A (es) | 2017-07-26 | 2017-11-23 | Laboratorios Liomont S A De C V | Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor. |
CN107556231A (zh) * | 2017-09-23 | 2018-01-09 | 江苏正大清江制药有限公司 | 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法 |
CN107417600A (zh) * | 2017-09-26 | 2017-12-01 | 江苏正大清江制药有限公司 | 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法 |
CN107898787B (zh) * | 2017-12-15 | 2018-11-30 | 扬子江药业集团上海海尼药业有限公司 | 一种药物组合物及其制剂和制备方法 |
WO2019130049A1 (en) | 2017-12-29 | 2019-07-04 | Grünenthal GmbH | Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain |
CN110143915A (zh) * | 2019-06-03 | 2019-08-20 | 蚌埠学院 | 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003484A1 (en) * | 1996-07-18 | 1998-01-29 | Merck Frosst Canada Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
WO1999055830A2 (en) * | 1998-04-24 | 1999-11-04 | Merck & Co., Inc. | Process for synthesizing cox-2 inhibitors |
WO2001037833A1 (en) * | 1999-11-29 | 2001-05-31 | Merck Frosst Canada & Co. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593994A (en) * | 1994-09-29 | 1997-01-14 | The Dupont Merck Pharmaceutical Company | Prostaglandin synthase inhibitors |
US5739166A (en) * | 1994-11-29 | 1998-04-14 | G.D. Searle & Co. | Substituted terphenyl compounds for the treatment of inflammation |
US5861419A (en) * | 1996-07-18 | 1999-01-19 | Merck Frosst Canad, Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
-
2001
- 2001-05-15 PH PH12001001175A patent/PH12001001175B1/en unknown
- 2001-05-16 AR ARP010102327A patent/AR028577A1/es unknown
- 2001-05-16 TW TW090111718A patent/TWI303634B/zh not_active IP Right Cessation
- 2001-05-16 GC GCP20011369 patent/GC0000362A/en active
- 2001-05-17 PE PE2001000443A patent/PE20011324A1/es not_active Application Discontinuation
- 2001-05-18 MY MYPI20012375 patent/MY123569A/en unknown
- 2001-05-21 GT GT200100091A patent/GT200100091A/es unknown
- 2001-05-22 ME MEP-2008-638A patent/ME00428B/me unknown
- 2001-05-22 GE GE5012A patent/GEP20053492B/en unknown
- 2001-05-22 IL IL15258201A patent/IL152582A0/xx active IP Right Grant
- 2001-05-22 KR KR20027015871A patent/KR100757699B1/ko active Protection Beyond IP Right Term
- 2001-05-22 JP JP2002500844A patent/JP3665053B2/ja not_active Expired - Lifetime
- 2001-05-22 JO JO200179A patent/JO2216B1/en active
- 2001-05-22 UA UA20021210537A patent/UA73355C2/uk unknown
- 2001-05-22 CZ CZ20023888A patent/CZ20023888A3/cs unknown
- 2001-05-22 SK SK1670-2002A patent/SK287174B6/sk not_active IP Right Cessation
- 2001-05-22 HU HU0302336A patent/HU228423B1/hu unknown
- 2001-05-22 EP EP01939267A patent/EP1296951B1/en not_active Expired - Lifetime
- 2001-05-22 WO PCT/US2001/016566 patent/WO2001092230A1/en active IP Right Grant
- 2001-05-22 ES ES01939267T patent/ES2351958T3/es not_active Expired - Lifetime
- 2001-05-22 CN CNB018101372A patent/CN1227233C/zh not_active Ceased
- 2001-05-22 RS YUP-894/02A patent/RS51541B/sr unknown
- 2001-05-22 CA CA002410234A patent/CA2410234C/en not_active Expired - Lifetime
- 2001-05-22 EE EEP200200655A patent/EE05242B1/xx unknown
- 2001-05-22 NZ NZ522394A patent/NZ522394A/en not_active IP Right Cessation
- 2001-05-22 DE DE60143197T patent/DE60143197D1/de not_active Expired - Lifetime
- 2001-05-22 AU AU2001264804A patent/AU2001264804B2/en not_active Expired
- 2001-05-22 DK DK01939267.9T patent/DK1296951T3/da active
- 2001-05-22 PT PT01939267T patent/PT1296951E/pt unknown
- 2001-05-22 PL PL01358153A patent/PL358153A1/xx not_active Application Discontinuation
- 2001-05-22 AT AT01939267T patent/ATE483687T1/de active
- 2001-05-22 SI SI200130982T patent/SI1296951T1/sl unknown
- 2001-05-22 BR BRPI0111140-0 patent/BRPI0111140B8/pt not_active IP Right Cessation
- 2001-05-22 PA PA20018516901A patent/PA8516901A1/es unknown
- 2001-05-22 AU AU6480401A patent/AU6480401A/xx active Pending
- 2001-05-22 MX MXPA02011619 patent/MX230696B/es active IP Right Grant
- 2001-05-22 EA EA200201264A patent/EA004809B1/ru not_active IP Right Cessation
- 2001-05-22 EG EG20010540A patent/EG24189A/xx active
- 2001-05-23 SV SV2001000462A patent/SV2002000462A/es active IP Right Grant
- 2001-05-23 HN HN2001000110A patent/HN2001000110A/es unknown
-
2002
- 2002-03-08 CR CR6606A patent/CR6606A/es unknown
- 2002-10-31 BG BG107237A patent/BG65855B1/bg unknown
- 2002-11-20 IS IS6630A patent/IS2806B/is unknown
- 2002-11-25 ZA ZA200209558A patent/ZA200209558B/en unknown
- 2002-11-25 HR HR20020934A patent/HRP20020934B1/xx not_active IP Right Cessation
- 2002-11-26 NO NO20025674A patent/NO324495B1/no not_active IP Right Cessation
- 2002-12-16 IN IN2089CH2002 patent/IN2002CH02089A/en unknown
- 2002-12-23 MA MA26971A patent/MA26919A1/fr unknown
-
2004
- 2004-03-10 HK HK04101751A patent/HK1058932A1/xx not_active IP Right Cessation
- 2004-09-10 JP JP2004263913A patent/JP4142621B2/ja not_active Expired - Lifetime
-
2007
- 2007-11-12 IN IN5103CH2007 patent/IN2007CH05103A/en unknown
-
2011
- 2011-01-04 CY CY20111100010T patent/CY1111440T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998003484A1 (en) * | 1996-07-18 | 1998-01-29 | Merck Frosst Canada Inc. | Substituted pyridines as selective cyclooxygenase-2 inhibitors |
WO1999055830A2 (en) * | 1998-04-24 | 1999-11-04 | Merck & Co., Inc. | Process for synthesizing cox-2 inhibitors |
WO2001037833A1 (en) * | 1999-11-29 | 2001-05-31 | Merck Frosst Canada & Co. | Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20020934B1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis | |
HRP20060361A8 (en) | Novel c-crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same | |
AP1452A (en) | Novel y crystalline form of perindopril tert-butylamine salt preparation method, and pharmaceutical compositions containing same. | |
HRP20000168B1 (en) | Resorcinol derivatives | |
CO5700731A2 (es) | Polimorfos cristalinos de un ligando receptor de cxc-quimiocina | |
JO2793B1 (en) | The new crystalline form 5 of agomelatine, its preparation process and the pharmaceutical ingredients it contains | |
CA2508824A1 (fr) | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent | |
WO2002080846A3 (en) | Epothilone derivatives and methods for making and using the same | |
IL181298A0 (en) | Solid and crystalline ibandronate sodium and processes for preparation thereof | |
CA2415438A1 (fr) | Forme cristalline .alpha. du sel de tert-butylamine du perindopril | |
BR0108947A (pt) | Método para preparação e citalopram; intermediário e sua composição farmacêutica | |
JO2493B1 (en) | New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses | |
HRP20000171B1 (en) | Oral compositions of levosimendan | |
BR0206372A (pt) | Processo para sintetizar um composto | |
WO2003049676A3 (en) | Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer | |
MXPA05008198A (es) | Composicion aclaradora de la piel. | |
MEP15708A (en) | Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof | |
NZ545580A (en) | Aminoquinoline derivatives and their use as adenosine A3 ligands | |
WO2001023377A3 (en) | Polymorphic salt | |
DE60206068D1 (de) | Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
TW200502235A (en) | Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof | |
CA2373962A1 (en) | Immediate release medicinal compositions for oral use | |
DE60234024D1 (de) | Neue retinoidderivate und eine pharmazeutische anti-krebs-zusammensetzung, die diese verbindungen enthält | |
KR870007930A (ko) | 5-치환된 옥타하이드로 인돌리진 및 그의 제조 방법 | |
WO2001080906A3 (en) | Radiometal complexes of 2-pyrrolylthiones for imaging a therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
PNAN | Change of the applicant name, address/residence |
Owner name: MERCK SHARP & DOHME CORP., US |
|
B1PR | Patent granted | ||
PNAN | Change of the applicant name, address/residence |
Owner name: SCHERING CORPORATION, US Owner name: MERCK SHARP & DOHME CORP., US |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190507 Year of fee payment: 19 |
|
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20200505 Year of fee payment: 20 |
|
PB20 | Patent expired after termination of 20 years |
Effective date: 20210522 |